Guangdong General Hospital

Institution (Healthcare)

Homepage Wikipedia ROR

Also Known As

Guangdong General Hospital, 广东省老年医学研究所 · Acronym: GGH

5.5K

Publications

478.9K

Citations

373

Authors

840

Concepts

About

Guangdong General Hospital is a healthcare institution in Guangzhou, China known for medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Health Sciences	53	463	30.4K
2	Engineering	41	184	10.8K
3	Language Studies	3	5	128
4	Arts	2	9	120
5	Education	2	10	308

Guangdong General Hospital

5.5K

Publications

478.9K

Citations

Page 1

	Year	Citations
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma Tony Mok, Yi‐Long Wu, Sumitra Thongprasert, New England Journal of Medicine	2009	8.2K
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study Caicun Zhou, Yi‐Long Wu, Gongyan Chen, The Lancet Oncology MedicinePathologyBronchial NeoplasmFirst-line TreatmentCancer Treatment	2011	4K
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer Alice T. Shaw, Dong‐Wan Kim, Kazuhiko Nakagawa, New England Journal of Medicine	2013	3.4K
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial Tony Mok, Yi‐Long Wu, Iveta Kudaba, The Lancet	2019	3.2K
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer Tony Mok, Yi‐Long Wu, Myung‐Ju Ahn, New England Journal of Medicine	2016	3.2K
CPAP for Prevention of Cardiovascular Events in Obstructive Sleep Apnea R. Doug McEvoy, Nick A. Antic, Emma Heeley, New England Journal of Medicine	2016	2K
Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial Yi‐Long Wu, Caicun Zhou, Chengping Hu, The Lancet Oncology Lux-lung 6MedicineRandomised Phase 3PathologyBronchial Neoplasm	2014	2K
The gut microbiome in atherosclerotic cardiovascular disease Zhuye Jie, Huihua Xia, Shilong Zhong, Nature Communications	2017	1.6K
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials James Chih‐Hsin Yang, Yi‐Long Wu, Martin Schüler, The Lancet Oncology Lux-lung 3Lux-lung 6MedicinePathologyBronchial Neoplasm	2015	1.6K
Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial Yi‐Long Wu, Ying Cheng, Xiangdong Zhou, The Lancet Oncology OncologyPathologyBronchial NeoplasmDacomitinib Versus GefitinibFirst-line Treatment	2017	1.2K

Page 1